

**AN EXPERIMENTAL STUDY ON INTRASTROMAL
INJECTION OF AMPHOTERICIN B IN *FUSARIUM*
SOLANI KERATITIS IN RABBITS**

**BY
DR. CHE MAHIRAN BINTI CHE DAUD
MD (USM)**

**Dissertation Submitted In Partial Fulfillment Of The
Requirements For The Degree Of Master Of Medicine
(OPHTHALMOLOGY)**



UNIVERSITI SAINS MALAYSIA

SCHOOL OF MEDICAL SCIENCES

UNIVERSITI SAINS MALAYSIA

2008

2. ACKNOWLEDGEMENT

To my supervisors Dr Liza Sharmini Ahmad Tajudin and Assc. Prof Mohtar Ibrahim, my sincere gratitude and deepest appreciation for their guidance, support and valuable advice throughout this study. Your commitment and contribution had made this study a success. Special thanks to Dr. Md Salzihan Md Salleh for his invaluable contribution and support in the histopathological analysis of this study.

Also thanks to Dr Siti Suraiya, Dr Rahim Sulong and Dr Rumaizi Shaari for their contribution. My thanks also go to the staffs of Animal Research Unit, USM.

To all lectures in the Ophthalmology Department, in particular Dr Wan Hazabbah Wan Hitam, Head of Ophthalmology Department, thanks for his teaching, guidance and encouragements throughout my course.

My husband, Nor Azuairi, thanks for all his time, help and encouragement. To my two lovely daughters, Emma Hanum and Intan Safiya, and my cute little son Nor Emir Arif, you were my inspirations. To my mum, Hasamah, no words can expressed my heartfelt gratitude for her help and time with us.

3. TABLE OF CONTENTS

1. DISCLAIMER	I
2. ACKNOWLEDGEMENT	II
3. TABLE OF CONTENTS	III
4. LIST OF FIGURES	IX
5. LIST OF TABLES	XIII
6. ABSTRAK	XVI
7. ABSTRACT	XVIII
CHAPTER 1 INTRODUCTION	1
1.1 BACKGROUND	1
1.2 FUNGAL KERATITIS	3
1.3 PREDISPOSING FACTORS	6
1.3.1 Trauma	6
1.3.2 Contact lenses	7
1.3.3 Topical steroid use	7
1.3.4 Other factors	8
1.4 LABORATORY DIAGNOSIS	8
1.4.1 Corneal scraping	9
1.4.2 Smear	9
1.4.3 Fungal culture	11
1.4.4 Polymerase Chain Reaction (PCR)	12

1.4.5	Confocal microscopy	12
1.4.6	Corneal biopsy	12
1.5	<i>FUSARIUM SPECIES</i>	13
1.5.1	Pathogenicity and clinical significance	14
1.5.2	Macroscopic features	14
1.5.3	Microscopic features	15
1.5.4	Susceptibility	15
1.6	PATHOGENESIS	16
1.6.1	Invasiveness	18
1.6.2	Morphogenesis	18
1.6.3	Toxigenicity	19
1.7	CLINICAL FEATURES	20
1.8	TREATMENT	21
1.8.1	Medical therapy	21
1.8.2	Surgical therapy	28
1.9	AMPHOTERICIN B	29
1.10	INTRASTROMAL INJECTION	33
CHAPTER 2	INTRODUCTION	35
2.1	GENERAL OBJECTIVE	35
2.2	SPECIFIC OBJECTIVES	35

CHAPTER 3	MATERIALS AND METHOD	36
3.1	RESEARCH STRATEGY	36
3.2	POPULATION, SETTING AND TIME	36
3.3	STUDY DESIGN	36
3.4	SAMPLING AND SAMPLE SIZE	37
3.4.1	Sampling method	37
3.4.2	Sample size	38
3.5	SELECTION CRITERIA	38
3.5.1	Inclusion criteria	38
3.5.2	Exclusion criteria	38
3.6	ETHICAL APPROVAL	38
3.7.	DEFINITION OF TERMS	39
3.7.1	Corneal ulcer	39
3.7.2	Fungal keratitis	39
3.7.3	Stromal infiltrates	40
3.7.4	Hypopyon	40
3.7.5	Fungi	40
3.7.6	Inoculum	40
3.7.7	Corneal toxicity	41
3.7.8	Superficial punctate keratopathy	41
3.8	STUDY INSTRUMENTS	41
3.8.1	Animals	41
3.8.2	Drugs and solutions	41

3.8.3	Surgical Instruments	42
3.8.4	Laboratory Instruments	43
3.8.5	Portable Slit Lamp	43
3.9.	METHODOLOGY	45
3.9.1	Phase 1: Preparation of stock culture	46
3.9.2	Phase 2: Inoculation of <i>Fusarium solani</i> and induction of keratitis	47
3.9.3	Phase 3: Preparation of Treatment	48
3.9.4	Phase 4: Treatment Protocol	49
3.9.5	Phase 5: Serial Clinical Examination	53
3.9.6	Phase 6: Enucleation	55
3.9.7	Phase 7: Gross section and histopathology examination	55
3.10	GUIDELINES	62
3.11	METHODS TO MINIMIZES ERROR	62
3.12	STATISTICAL ANALYSIS	62
CHAPTER 4	RESULTS	65
4.1	SUBJECT CHARACTERISTICS	65
4.2	SERIAL CLINICAL EXAMINATION	65
4.2.1	Size of Epithelial Defect	68
4.2.2	Depth of Ulcer	71
4.2.3	Stromal Infiltrate	74
4.2.4	Hypopyon	77
4.2.5	Satellite Lesion	80

4.2.6	Corneal toxicity	83
4.3	STATISTICAL ANALYSIS BETWEEN AND WITHIN GROUPS	85
4.4	HISTOPATHOLOGY EXAMINATION	88
4.4.1	Depth of Corneal Involvement	88
4.4.2	Fungal Load	92
4.4.3	Fungal Orientation	94
4.4.4	Degree of Inflammatory Response	95
4.4.5	Types of inflammatory cells infiltration	98
4.4.6	Granulation	100
4.4.7	Tissue Necrosis	102
CHAPTER 5	DISCUSSIONS	103
CHAPTER 6	CONCLUSIONS	114
CHAPTER 7	REFERENCES	115
APPENDICES		128
APPENDIX 1:	STAINING METHODS	128
1.	Haematoxylin and eosin staining method	128
2.	Grocott-Gomori methenamine silver method for fungi	129
3.	PAS staining technique	131

APPENDIX 2	DATA COLLECTION SHEET & RESULTS	133
A.	SERIAL CLINICAL EXAMINATION RESULTS	133
B.	PATHOLOGICAL ANALYSIS RESULTS	138

4. LIST OF FIGURES

		Page
Figure 3.1	Portable slit lamp	44
Figure 3.2	Rabbits were kept in individual cage with treatment label attached to the cage door	48
Figure 3.3	Portable slit lamp is used to examine and confirm the development of fungal keratitis post inoculation	50
Figure 3.4	Rabbit with fungal keratitis post successful inoculation (K = keratitis, H = Hypopyon)	50
Figure 3.5	Injection of the intrastromal Amphotericin B in the rabbit guided by the portable slit lamp	52
Figure 3.6	The injection of intrastromal Amphotericin B (K – area of epithelial defect, C – clear cornea)	52
Figure 3.7	Post intrastromal injection showing immediate cornea hydration	53
Figure 3.8	Light microscopy photographs of fungal keratitis (stain, hematoxylin-eosin X 25) showing areas of induced ulceration (U) with intense inflammation and necrosis (I) underneath and adjacent vascularised granulation tissue formation (G)	57

Figure 3.9	Light microscopy photographs of fungal keratitis (stain, PAS X 25) showing numerous fungal hyphae (H)	58
Figure 3.10	SPSS version 12.0 for Windows was used in the statistical analysis	64
Figure 3.11	The General Linear Model (GLM) Repeated Measures module that was used to analyse the significance difference (<i>p</i> value)	64
Figure 4.1	Overall mean clinical score for all treatment groups	67
Figure 4.2	The mean score progression of size of the epithelial defect according to the treatment group	69
Figure 4.3	The mean score changes of the depth of ulcer according to treatment groups	72
Figure 4.4	The mean score changes of stromal infiltrates according to treatment groups	75
Figure 4.5	Changes in mean score of hypopyon according to the treatment groups	78
Figure 4.6	The grading of satellite lesion according to the treatment groups	81
Figure 4.7	Corneal descemetocoele, thinning demonstrated by Group A and B, while Group C subject showed resolution of corneal ulcer with area of corneal opacity after treatment	84

Figure 4.8	Light microscopy photographs of fungal keratitis (stain, hematoxylin-eosin X 25) showing anterior 2/3 (A) of corneal involvement characterised by the presence of inflammatory cells (Epithelial (EN), Endothelial (EN))	89
Figure 4.9	Light microscopy photographs of fungal keratitis (stain, PAS X 25) showing posterior 1/3 (P) corneal involvement characterised by the intense inflammatory reaction (Endothelial (EN))	90
Figure 4.10	Light microscopy photographs of fungal keratitis (stain, hematoxylin-eosin X 25) showing diffuse corneal involvement including anterior chamber (AC)	91
Figure 4.11	Filamentous <i>Fusarium</i> species (stain with PAS X 25) demonstrating branching and segmented fungal bodies (purplish in colour (F))	93
Figure 4.12	Section of the cornea from one of the subjects in Group B showing intense inflammation (polymorphnuclear - PMN) with absence of fungal hyphae (stain with PAS X 50)	96
Figure 4.13	Section of the cornea taken from one of the subjects in Group C showing mild inflammatory response (stain with H&E X 50)	97
Figure 4.14	Section of the cornea taken from Group C (stain, PAS X 100) showing presence of PMN and LMN	99

Section of the cornea taken from a subject of Group B (stain, PAS X 25) showing presence of marked granulation tissue with intense inflammation (G). (S – stromal, E – epithelial)

5. LIST OF TABLES

		Page
Table 1.1	Antimicrobial activity of antifungal agents based on published reports	22
Table 1.2	Susceptibility data for keratitis fungal isolates (Bascom Palmer Eye Institute)	23
Table 3.1	Clinical grading scheme for severity of corneal ulcers (Kaufman HE, 1988)	54
Table 3.2	Histopathological grading for pattern of inflammatory response in corneal buttons with fungal keratitis	60
Table 3.3	Density and distribution of fungal filament in cornea button with fungal keratitis	61
Table 4.1	Overall mean, standard deviation and p values for all treatment groups	66
Table 4.2	Significant difference (<i>p</i>) comparison between different treatment groups	66
Table 4.3	Clinical score for size of epithelial defect at day 3 and day 14	69
Table 4.4	Means and standard deviations for size of the epithelial defect between treatment groups	70
Table 4.5	Comparison of the size of the epithelial defect between treatment groups	70

Table 4.6	Clinical score for depth of ulcer at day 3 and day 14 according to post treatment examination	72
Table 4.7	Means and standard deviations for the depth of the ulcer between treatment groups	73
Table 4.8	Clinical score for infiltration at day 3 and day 14 post treatment	75
Table 4.9	Means and standard deviations in corneal infiltration between treatment groups	76
Table 4.10	Comparison of grading of the corneal infiltrate between treatment groups	76
Table 4.11	Grading of hypopyon at day 3 and day 14 post treatment	78
Table 4.12	Means and standard deviations in grading of hypopyon between treatment groups	79
Table 4.13	Comparison of grading of hypopyon between different treatment groups	79
Table 4.14	The grading of satellite lesion at day 3 and 14 post treatment	81
Table 4.15	Means and standard deviations in grading of satellite lesion between treatment groups	82
Table 4.16	Comparison of grading of satellite lesion between treatment groups	82
Table 4.17	Analysis of grading size of the epithelial defect between and within treatment groups	85

Table 4.18	Analysis of grading the depth of the ulcer between and within treatment groups	85
Table 4.19	Analysis of grading the corneal infiltration between and within treatment groups	86
Table 4.20	Analysis of the grading of hypopyon between and within treatment groups	86
Table 4.21	Analysis of the grading of satellite lesion between and within treatment groups	87
Table 4.22	The depth of corneal involvement among the treatment groups at day 14 post treatment	88
Table 4.23	The histopathology score of fungal load at day 14 post treatment according to treatment groups	92
Table 4.24	The histopathology score for fungal orientation post treatment at day 14 according to treatment groups	94
Table 4.25	The histopathological score of the degree of inflammation at day 14 post treatment according to the treatment groups	95
Table 4.26	Type of inflammatory cells infiltration at day 14 according to the treatment groups	98
Table 4.27	The histopathology score of granulation at day 14 post treatment according to the treatment groups	100
Table 4.28	The histopathology score of tissue necrosis at day 14 post treatment according to the treatment groups	102

6. ABSTRAK

Objektif:

Untuk membuat perbandingan keberkesanan diantara suntikan intrastromal amphotericin B 0.0005% (5µg/ml) dan suntikan intrastromal amphotericin B 0.15% (1.5mg/ml) serta untuk memastikan suntikan intrastromal amphotericin B adalah selamat di dalam ulser mata '*Fusarium solani*' pada mata arnab.

Tatacara:

Ulser mata diaruhkan melalui prosedur inoculasi yang telah ditetapkan untuk *Fusarium solani* ke atas lapisan kornea yang telah dikikis pada 18 ekor arnab. Kumpulan A (n=6) diberi rawatan titisan ubat amphotericin B 0.15% (kawalan) selama 12 jam sehari. Manakala kumpulan B (n=6) diberi rawatan suntikan intrastromal amphotericin B 0.15% dan kumpulan C (n=6) diberi rawatan suntikan intrastromal 0.0005% pada hari ke 3, 6, 9 dan 11. Selepas rawatan, pemeriksaan bersiri dijalankan untuk melihat perubahan pada saiz ulser, ketebalan ulser, infiltrasi stromal, 'hypopyon', dan lesi satelit selama 14 hari. Pada hari ke-14, enukleasi dijalankan dan dihantar ke makmal untuk pemeriksaan patologi.

Keputusan:

Kumpulan yang diberi rawatan dengan suntikan intrastromal amphotericin B 0.0005% didapati lebih efektif berbanding dengan kumpulan yang diberi rawatan suntikan intrastromal 0.15% ($p < 0.001$). Pemeriksaan bersiri menunjukkan perubahan ketara pada saiz ulser ($p = 0.01$) dan lesi satelit (0.02). Hasil pemeriksaan patologi

menunjukkan tiada fungi, ketebalan ulser setakat anterior dua per tiga, inflamasi sederhana dan minimal granulasi pada kumpulan yang diberi rawatan suntikan intrastromal 0.0005% amphotericin B. Tiada tanda-tanda dikompensasi pada kornea, 'punctate keratopathy' yang teruk atau 'corneal melting' yang dilihat pada kumpulan yang diberi rawatan suntikan intrastromal 0.0005%.

Kesimpulan:

Suntikan intrastromal Amphotericin B 0.0005% (5µg/ml) adalah efektif dan selamat pada kornea untuk rawatan ulser mata '*Fusarium solani*'. Adalah dicadangkan penggunaannya kepada pesakit yang tidak berkesan dengan rawatan ubat titisan. Ianya juga boleh mengurangkan kos serta mengurangkan masa rawatan di hospital.

7. ABSTRACT

Objective:

To compare the effectiveness between intrastromal injection of amphotericin B 0.15% (1.5mg/ml) and intrastromal injection of amphotericin B 0.0005% (5µg/ml) and the safety of intrastromal injection Amphotericin B 0.0005% in *Fusarium solani* keratitis in rabbits.

Methodology:

Fungal keratitis was induced with a standardized inoculum of *Fusarium solani* placed on the debrided cornea into the right eye of 18 New Zealand white rabbits. Rabbits in Group A (n=6) were treated with topical 0.15% amphotericin B every hourly for 12 hours daily (control), while rabbits in Group B (n=6) were treated with intrastromal injection 0.15 % (1.5mg/ml) of amphotericin B and Group C rabbits (n=6) were treated with intrastromal injection 0.0005% (5µg/ml) of amphotericin B. The intrastromal injection was given at day 3, 6, 9 and 11. Serial clinical examination was conducted at day 3, 6, 9, 11 and 14 to look at the changes in the size of the epithelial defect, the depth of the ulcer, stromal infiltration, hypopyon and the presence of satellite lesion. The infected eyes were enucleated on the day 14 and sent for histopathology evaluation.

Results:

The intrastromal injection of amphotericin B 0.0005% injection (group C) was found to be effective compared to intrastromal injection amphotericin B 0.15% ($p < 0.001$) in treating *Fusarium* keratitis in rabbits. There was statistical significant difference in the size of epithelial defect ($p = 0.02$) and satellite lesion ($p = 0.02$) for the rabbits treated with intrastromal injection of amphotericin B 0.0005% compared to the intrastromal injection of amphotericin B 0.15%. Histopathological examination also revealed absence of fungal load, the depth of ulcer limited to anterior two third, moderate inflammatory responses and mild granulation tissue in the group treated with intrastromal injection amphotericin B 0.0005%. These histopathological findings were consistent with serial clinical observation. There was no evidence of corneal decompensation, severe punctate keratopathy and or corneal melting in the group treated with intrastromal injection amphotericin B 0.0005%.

Conclusion:

Intrastromal injection of amphotericin B 0.0005% (5µg/ml) was found to be effective and safe in treating *Fusarium solani* keratitis. Thus, after undergoing clinical trial it can be applied to the patient whose refractory to conventional therapy and can reduce the cost and shorten the hospital stay.

Chapter 1

Introduction

1.1 BACKGROUND

Fungal keratitis represents one of most difficult forms of microbial keratitis for ophthalmologist to diagnose and treat successfully. The key challenges include making the correct diagnosis based on the clinical characteristics of fungal keratitis, and the problems with the effectiveness of anti fungal drugs. The problems can be further complicated with late presentation associated with advanced infection, which may lead to poor vision and loss of vision.

Till now there is no precise guidelines for drug therapy have been established. There are several factors that were recognized to limit the efficacy of antifungal agents. One factor is the sensitivity of the infection to the specific antifungal therapy is not well established. Furthermore the penetration of antifungal agents into and through the cornea, bioavailability and delivery of the drug and toxicity of the antifungal agents are difficult to quantify.

In general, the antifungal agents are of low solubility and penetrate non-lipid layer poorly. The agents tend to be toxic at adequate therapeutic concentration lead to difficulty to determine the appropriate concentration. There is marked and noticeable variability between in vitro sensitivity patterns and in vivo efficacy. In addition, the pharmacokinetics, the effect of the immune response, and other drug interactions are not well understood.

The major group of antifungal agents are polyenes such as amphotericin B, natamycin, and nystatin; the azoles including clotrimazole, miconazole, ketoconazole and fluconazole. The current selection of antifungals is based on animal experiments, clinical experience, and published sensitivity data (O'Day et al, 1987). In vitro sensitivity testing of a particular isolate is rarely indicated. The data obtained from individual testing are difficult to interpret, and expensive to set up. In addition, by the time results are obtained, the clinical appearance of keratitis will determine whether it is responding to medical treatment or whether surgery is indicated. Recent study suggests that careful monitoring of infiltrate and antifungal testing may play a role in outcome of treatment (Vemuganti et al, 2002).

Although natamycin was found to be effective in treating *Fusarium solani* keratitis (Jones, et al, 1972), but there are recent concerns regarding natamycin resistance and inability to treat deep stromal keratitis. In addition, the cost is high. A 5 ml of natamycin cost around RM400, usually more than a bottle is needed to eradicate this highly virulent fungal infection, which brings the cost higher. For these reasons, topical amphotericin B remains a potent agent in treating *Fusarium* keratitis. It has wider spectrum of activity. Furthermore, topical Amphotericin B 0.15%, which is inexpensive, readily available and is sufficient to treat fungal keratitis without ocular toxicity from higher concentration (Wood et al, 1976).

In general, the clinical efficacy of an antifungal agent depends to a great extent on the concentration achieved in the target ocular tissue. It depends on the molecular mass, concentration of the drugs, route of administration, the duration of contact with the target ocular tissue, and the ability of the compound to penetrate the eye (Thomas et al, 2003). Perhaps the intrastromal 0.0005% (5µg) injection of amphotericin B will improve the corneal concentration and increase the effectiveness in eradication of deep fungal ulcer.

1.2 FUNGAL KERATITIS

Corneal diseases are the major cause of vision loss and blindness, after cataract in overall importance (Whitcher et al, 2001). The World Health Organisation (WHO) has estimated that ocular trauma and corneal ulceration result in 1.5 to 2 million new cases of corneal blindness annually (Whitcher et al, 2001). In the warm climate developing agriculture-based countries; the commonest form of diseases affecting the cornea is fungal keratitis.

Fungal keratitis is an inflammation of cornea caused by fungal which is characterized by elevated areas, hyphae (branching) ulcers, irregular feathery margins, a dry rough texture, and satellite lesion. According to fungal morphology, fungal can be divided into four groups; nonpigmented filamentary fungi including *Fusarium spp* and *Aspergillus spp*; pigmented filamentary fungi including *Curvularia spp* and *Lasiodiplodia spp*; yeasts such as *Candida spp.* and filamentous non septated such as *Rhizopus* (mucormycosis).

The incidence of fungal keratitis varies geographically, but commonly occurs in warm, tropical climates. It is the major blinding eye disease in Asia (Khairallah et al, 1992, Srinivasan et al, 1991, Upadhyay et al, 1991) and leading cause of ocular morbidity. In two series of suppurative keratitis in North India, between 17 to 36% were of fungal etiology (Dunlop et al, 1994, Upadhyay et al, 1991). Similar finding was also found in similar studies conducted in Nepal (17%), Bangladesh (36%), Ghana (37%) (Upadhyay et al, 1991; Dunlop et al, 1994).

In a larger series from South Florida, fungal keratitis accounted for 20% of suspected microbial keratitis (Liesegang et al, 1980). In tropical regions, the most common organisms responsible for fungal keratitis are *Fusarium* and *Aspergillus* species (Leck et al, 2002). While, in temperate regions, where fungal keratitis is less common, yeast was isolated in 32%-72% of cases (Leck et al, 2002; Ritterband et al, 2006) and the incidence of fungal keratitis remains low (Coster et al, 1981; Asbell et al, 1982).

Fusarium species are most important etiology agent of fungal keratitis in South Florida; however in Asian series the predominant organisms seem to be *Aspergillus* species, reported in 35 to 47% (Khairallah et al, 1992, Srinivasan et al, 1991; Upadhyay et al, 1991).